Products with Cardioprotective bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1212 | Secoisolariciresinol Diglucoside |
| Secoisolariciresinol diglucoside(SDG) is a phytoestrogen, estrogens and phytoestrogen from soy have been reported to have mild hypotensive effects, and SDG is a long-acting hypotensive agent, and that the hypotensive effect is mediated through the guanylate cyclase enzyme. SDG has strong antioxidant activity, cardioprotective effects, reduces the blood levels of low-density lipoprotein cholesterol, and reduces the risk of hormone related cancer. | |
| BCN1254 | (20S)-Protopanaxdiol |
| 20(S)-Protopanaxdiol may be a potential new P-gp inhibitor for cancer treatment, it may induce the apoptosis via the down-regulation of Bcl-2 protein and the up-regulation of γH2Ax protein expression; it may inhibit the proliferation of Siha cells via the up-regulating the expressions of p53, p21, and autophagy related gene Beclin 1and MAP1-LC3, and down-regulating the expression of cyclin-E. | |
| BCN1256 | Asperosaponin VI |
| Asperosaponin VI has antioxidant activity, it shows protective effect against hypoxia-induced cardiomyocytes apoptosis probably by activating the PI3K/Akt and CREB pathways, it also plays protective roles on acute myocardial infarction in rats. Asperosaponin VI may induce osteoblast maturation and differentiation, and then increase bone formation via increasing BMP-2 synthesis, and activating p38 and ERK1/2. | |
| BCN1279 | (-)-Bilobalide |
| Bilobalide possesses anticonvulsant, insecticidal, and cardioprotective effects. Bilobalide exerts protective and trophic effects on neurons, the PI3K/Akt pathway may be involved in the protective effects of bilobalide; it also can protect PC12 cells from A beta 25-35-induced cytotoxicity, it dose-dependently attenuates the cytotoxic effect of A beta 25-35. | |
| BCN1653 | Rocaglaol |
| 1. Rocaglaol is a cytotoxic cyclopenta[b]benzofuran, shows in vitro cytotoxic activity against Lu1, LNCaP and MCF-7 cells with ED50 values of 13.8, 23.0 and 9.2 nM, respectively. 2. Rocaglaol is a potent anticancer drug that induces apoptosis of LNCaP cells through the mitochondrial pathway and its G2/M-phase cell cycle arrest is associated with the down-regulation of Cdc25C and the dephosphorylation of Cdc2. 3. Rocaglaol can reduce tissue inflammation and neuronal cell death by inhibiting NF-kappa B and AP-1 signaling, resulting in significant neuroprotection in animal models of neurodegeneration. 4. Rocaglaol derivatives can prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent. 5. Rocaglaol, pyrimidinone and aglaiastatin are potent inhibitors of the growth of K--cells, with IC50 values of 1-10 ng/mL, and induce normal morphology in K--cells at 10-30 ng/mL, they also specifically inhibit protein synthesis. | |
